



From the Desk of President

Dear Friends

I would like to take this opportunity to share my views on some of the important developments and concerns presently shaping our industry.

The industry must acknowledge the continued digital transformation initiatives undertaken by CDSCO and other regulatory authorities. Though the industry may be facing certain practical challenges during the initial stages of implementation, the migration of several approval processes to online platforms will certainly improve transparency, accessibility, and efficiency in the long run. In particular, the efforts made by CDSCO in streamlining applications for WHO-GMP certifications and CoPPs through the ONDLS portal are appreciable. At BDMAI, we are making continuous efforts to bring the issues faced by the industry to the notice of the authorities so that appropriate solutions can be evolved at the earliest.

The recent environmental policy clarifications issued by the MoEF & CC have also brought considerable relief to the industry. The clarification that Environmental Clearance may not be required in certain cases involving changes in product mix, subject to "No Increase in Pollution Load," is a pragmatic and progressive step. In furtherance of these positive initiatives, BDMAI has requested the Pollution Control Boards to do away with the requirement of Consent to Establish and to make the process for Consent to Operate completely online in cases involving changes in product mix. Such reforms would significantly improve ease of doing business while ensuring environmental compliance.

Government of India, through the Export Promotion Mission, has recently launched several schemes intended to support MSME exporters, including Interest Subvention on Pre and Post Shipment Export Credit, CGSE, TRACE, MAS, FLOW, and other initiatives. While these schemes are appreciable and reflect the Government's intent to strengthen exports, many MSME manufacturers feel that the extent of financial assistance presently available is only a small fraction of the actual expenditure incurred towards compliance, certifications, market development, financing costs, and international business promotion activities. As a result, in several cases, these schemes remain underutilized. Recently, BDMAI made a representation to the Government requesting inclusion of all HS Codes under the Interest Subvention Scheme so that the benefits can reach a wider section of exporters. There is a need for wider coverage, simplified implementation procedures, and more meaningful financial support so that genuine MSME exporters can effectively benefit from these initiatives and improve their competitiveness in global markets.

Thanking you and looking forward to your continued interaction and support to BDMAI.

With warm regards

Ch A P Rameswara Rao
National President

In this Bulletin
you can expect

Global Pharma News

New Drug
Developments,
Investments & JVs
Drug Approvals,

BDMAI Activities

Representations
Circulars
Events
Govt Notifications

Technical / Commercial Articles

Data of
Import & Export
of Bulk Drugs

New Drug Developments:

Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease

Amgen has announced positive topline findings from a phase 3 study evaluating a subcutaneous formulation of Tepezza in adults with moderate to severe active thyroid eye disease (TED). The company said the on-body injector version delivered efficacy comparable to the intravenous formulation, which is currently the only approved treatment for the condition. The phase 3 trial met its primary endpoint, with a statistically significant and clinically meaningful proptosis response rate of 76.7 percent at week 24 compared with 19.6 percent for placebo. Mean proptosis reduction reached 3.17 mm, exceeding the threshold regarded as clinically meaningful.

Pharma Times 7.4.2026
[Read More](#)

CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment

CatalYm has dosed the first patient in its global GDFATHER-HCC-01 study, a phase 2b trial evaluating visugromab in combination with chemoimmunotherapy for people with unresectable or metastatic hepatocellular carcinoma who have progressed after first-line anti-PD-(L)1

therapy. The study will test visugromab alongside nivolumab and the tyrosine kinase inhibitor lenvatinib. It begins with an open-label safety run-in to confirm the recommended dose for expansion, followed by a randomized, double-blind phase comparing the triple combination with double placebo plus lenvatinib. Visugromab is designed to neutralise GDF-15, an immunosuppressive cytokine used by tumour cells to evade immune attack. CatalYm notes that restoring immune sensitivity could be particularly valuable in a setting where long-term survival remains poor. Earlier data from the exploratory phase 1/2a GDFATHER trial showed what the company described as encouraging anti-tumour activity when visugromab was combined with an anti-PD-1 antibody.

Pharma Times 7th April 2026
[Read More](#)

Interna, Daiichi Sankyo Partner to Advance Drug Delivery Innovation

Interna Therapeutics has entered into a new research collaboration with Daiichi Sankyo to explore next-generation approaches to intracellular drug delivery, marking another step forward in efforts to improve the effectiveness of targeted therapies. The agreement, announced by the clinical-stage biotechnology firm, will focus on evaluating Interna's proprietary Molecular Nano Motor (MNM) platform as a delivery enhancer for a range of therapeutic modalities. The collaboration will be conducted through Daiichi Sankyo's Boston-based research arm and will initially center on preclinical studies. Under the terms of the partnership, both companies will work to integrate MNM molecules with advanced targeting strategies. programs.

Pharma Journalist 17.4.2026
[Read More](#)

M&A/JVs

Gilead outlays \$5bn to acquire ADC specialist Tubulis

Gilead will acquire antibody-drug conjugate (ADC) developer Tubulis in a deal worth up to \$5bn, continuing the big pharma company's recent string of high-profile M&A activity in 2026.

As per the agreement, Gilead will pay \$3.15bn upfront and up to \$1.85bn in milestones to buy the German biotech. Following the transaction's close, set for Q2 2026, Tubulis will become an ADC research organisation within Gilead. Tubulis' catalogue of drugs is headed by TUB-040, a NaPi2b-directed topoisomerase-I inhibitor (TOPO1i) ADC that is currently in Phase Ib/II trials for platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). The asset produced positive safety and efficacy results in the former indication in early data shared in October 2025. Gilead will also acquire TUB-030, a 5T4 targeted ADC for solid tumour treatment, as well as other assets that are being developed for undisclosed cancer indications.

Pharmaceutical Technology 8.4.206
[Read More](#)

Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb

Oxford BioTherapeutics has entered a multi-year collaboration with Bristol Myers

Squibb to discover and develop novel T-cell engager therapies for solid tumours, marking the company's third major pharma partnership in 12 months. The agreement will see OBT apply its OGAP-Verify discovery and validation platform to identify tumour-selective targets and generate next-generation T-cell engager molecules. The company will also design and deliver development candidates, reflecting its expansion into a fully integrated discovery and preclinical development organisation. BMS will lead subsequent research, development and commercialisation. Under the terms of the deal, OBT will receive an upfront payment inclusive of research funding, along with potential milestone payments and royalties on commercialised products. Financial details were not disclosed.

Pharma Times 9.4.2026
[Read More](#)

EverSea Medicines to acquire Hasten Biopharmaceuticals

Everest Medicines' wholly owned subsidiary EverSea Medicines (Singapore) has signed a share purchase agreement to conditionally acquire Hasten Biopharmaceuticals, a subsidiary of Hasten Biopharmaceuticals (Asia). The acquisition aims to enhance Everest Medicines' presence and commercial capabilities across key regional markets. Under the deal, Everest Medicines will pay a total consideration of \$250m in three instalments: \$150m at closing, and two further \$50m payments due in the first quarters of 2028 and 2029, subject to agreed conditions precedent.

Pharmaceutical Technology 9.4.2026
[Read More](#)

Aligos and Xiamen Amoytop sign deal for HBV therapy

Aligos Therapeutics has signed an exclusive licence agreement with Xiamen Amoytop Biotech for the development and commercialisation of pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection. This territory includes Hong Kong, Macau, Mainland China, and Taiwan. The focus of the partnership is to address the needs of more than 90 million people affected by HBV in this region. Under the agreement, Aligos will receive an upfront milestone payment of \$25m.

Pharmaceutical Technology 17.4.2026
[Read More](#)

Piramal, Ajinomoto Partner to Advance ADC Manufacturing Capabilities

Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services have announced a strategic collaboration aimed at strengthening capabilities in the rapidly growing field of antibody-drug conjugates (ADCs), a promising class of targeted cancer therapies. The partnership is designed to create a more integrated ecosystem for pharmaceutical companies developing ADCs by combining Piramal's extensive manufacturing expertise with Ajinomoto's proprietary AJICAP™ technology. Under the agreement, Piramal will refer clients seeking ADC manufacturing technologies to Ajinomoto, particularly those interested in leveraging AJICAP™, while Ajinomoto will direct customers to Piramal as a preferred contract development and manufacturing

organization (CDMO) for producing therapies using this platform

Pharma Journalist 17.4.2026
[Read More](#)

Aligos and Xiamen Amoytop sign deal for HBV therapy

Aligos Therapeutics has signed an exclusive licence agreement with Xiamen Amoytop Biotech for the development and commercialisation of pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection. This territory includes Hong Kong, Macau, Mainland China, and Taiwan. The focus of the partnership is to address the needs of more than 90 million people affected by HBV in this region. Under the agreement, Aligos will receive an upfront milestone payment of \$25m.

Pharmaceutical Technology 17.4.2026
[Read More](#)

Leinco, CellCarta Partner to Advance Proteomics in Oncology

Leinco Technologies and CellCarta have announced a strategic collaboration to enhance proteomics solutions aimed at supporting immuno-oncology research and the development of targeted therapies. The partnership brings together complementary expertise in antibody development and advanced protein analysis, with the goal of accelerating biomarker discovery and improving clinical research capabilities. At the core of the collaboration is the integration of Leinco's extensive portfolio of high-quality

antibodies with CellCarta's specialized Immuno-MRM (multiple reaction monitoring) assay platform. Leinco's antibodies are widely used in applications such as immunohistochemistry (IHC) and emerging spatial biology technologies, both of which are critical for studying tissue-specific protein expression. By combining these validated tools with CellCarta's highly multiplexed and quantitative Immuno-MRM assays, the companies aim to provide a more comprehensive and precise approach to proteomic analysis

Pharma Journalist 24.4.2026
[Read More](#)

Eli Lilly outlays \$2.3bn to acquire blood cancer specialist Ajax Therapeutics

Eli Lilly has added yet another string to its M&A bow of 2026 after agreeing to acquire cancer specialist Ajax Therapeutics in a deal worth up to \$2.3bn. The sum being paid by Lilly for US-based Ajax includes an upfront fee as well as clinical and regulatory milestones, though the breakdown of the financials was not disclosed by either company. In Ajax, Lilly has secured a company developing treatments for myeloproliferative neoplasms (MPNs), a group of rare blood cancers where the bone marrow produces too many red blood cells.

Pharmaceutical Technology
[Read More](#)

Sun Pharma to acquire Organon at EV of US\$ 11.75 billion

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, "Sun Pharma") and Organon & Co. (NYSE: OGN) ("Organon") today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US\$ 14.00 per share in an all-cash transaction with an enterprise valuation of US\$ 11.75 billion. Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women's health, the company's portfolio includes more than 70 products across Women's Health and General Medicines, which includes biosimilars, commercialized across 140 countries, with the U.S., Europe, China, Canada, and Brazil among its largest markets. This global footprint is supported by six manufacturing facilities across the European Union and emerging markets, reinforcing its scale and reach. Together, Organon's General Medicines and Women's Health franchise reflect the company's commitment to advancing access and affordability for communities around the world.

Business Wire 26.4.2026
[Read More](#)

Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy

Kahimmune Therapeutics has signed a scientific collaboration agreement with Gustave Roussy to support the selection and development of its first shared mRNA companion neoantigen therapy candidate, KAH-001, targeting colorectal and pancreatic cancers. The company, co-founded by Gustave Roussy Transfert, develops next-generation immuno-oncology therapies that exploit the dark genome to identify exclusive new neoantigens. These are designed for use alongside existing cancer treatments to improve their safety and effectiveness. Under the agreement, Kahimmune will gain access to patients' biological samples to generate preclinical data and select the antigens that will form KAH-001 by mid-2027. The company will then begin preclinical development and CMC activities to produce an mRNA-LNP clinical candidate, with regulatory preclinical development planned by mid-2029.

Pharma Times 29.4.2026
[Read More](#)

DRUG APPROVALS

Bayer wins MHRA approval for Kerendia in heart failure

Bayer has received MHRA approval for Kerendia (finerenone) for adults in the UK with symptomatic chronic heart failure and a left ventricular ejection fraction of 40% or

above. The decision covers both heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction, two phenotypes that together account for around half of all UK heart failure cases. Dr Fozia Ahmed, Consultant Cardiologist at Manchester University NHS Foundation Trust, said: "Heart failure with preserved ejection fraction and heart failure with mildly reduced ejection fraction remain among the most challenging forms of heart failure to manage in everyday clinical practice.

Pharma Times 13.4.2026
[Read More](#)

Travere Therapeutics gains FDA approval for sparsentan in FSGS

Travere Therapeutics has received the US Food and Drug Administration (FDA) full approval for Filspari (sparsentan) to reduce proteinuria in adult and paediatric patients aged eight years and above with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. The approval makes Filspari the first and only FDA-approved medicine to treat FSGS, expanding its use beyond IgA nephropathy (IgAN) into a second rare kidney condition. FSGS is a rare disease, and patients without nephrotic syndrome include a group consistent with kidney disease: improving global outcomes (KDIGO) guidelines for glomerular diseases.

Pharmaceutical Technology 14.4.2026
[Read More](#)

MHRA approves Bayer's treatment for symptomatic heart failure

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Bayer's Kerendia® (finerenone), a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), for the treatment of symptomatic chronic heart failure (HF) with left ventricular ejection fraction (LVEF) $\geq 40\%$, in adults in the UK. UK marketing authorisation is based on results from the Phase III FINEARTS-HF study investigating the efficacy and safety of finerenone for the prevention of cardiovascular death and heart failure events in adult patients with HF with LVEF $\geq 40\%$. The new indication covers both the heart failure phenotypes of heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF).

Pf Media
[Read More](#)

22.4.2026

UK medicines regulator grants authorisation to Enflonsia for RSV prevention

The UK's Medicines & Healthcare Products Regulatory Agency has granted marketing authorisation to Enflonsia (clesrovimab), MSD's monoclonal antibody for preventing respiratory syncytial virus lower respiratory tract disease in neonates and infants during their first RSV season. Clesrovimab is the first monoclonal antibody designed to protect infants with a single dose regardless of weight, providing coverage for the duration of their first RSV

season. Before the national immunisation programme for infants and older adults was introduced in 2024, RSV was responsible for around 30,000 hospitalisations each year in children under five and 20 to 30 infant deaths.

Pharma Times 27.4.2026

[Read More](#)

Arrowhead's Redemplo secures Australian TGA approval for FCS therapy

Arrowhead Pharmaceuticals has received approval from the Australian Therapeutic Goods Administration (TGA) for Redemplo (plozasiran) to treat familial chylomicronemia syndrome (FCS). The therapy is approved as an add-on to diet, specifically for adults with FCS whose triglyceride levels remain high despite standard triglyceride-lowering treatments. The approval marks an expansion of access for a genetic disorder estimated to affect one to 13 people per million worldwide.

Pharmaceutical
[Read More](#)

Technology

4.5.2026

ASSOCIATION ACTIVITIES

Circulars

1	6.5.2026	Video on Filing of WHO GMP/CoOos on ONDLS Portal
2	28.4.2026	Scientific Conclave & Interactive Session on Indian Pharmacopeia 2026
3	16.4.2028	Interest Subvention for Pre-and Post Shipment Exports credit for MSME Exporters
4	8.4.2026	Allotment of space at BDMAI;s Technology & Training Center, Jeedimetla to the interest members of BDMAI

Representations:

BDMAI made the following representations during April-May 2026.

1	8.5.2026	Request for exemption of regular approvals for DG sets installed for Safety Purpose
2	22.4.2026	Interest subvention for pre and post export credit – request for inclusion of all HS codes
3	22.04.2026.	Allocation of Ammonia to Bulk Drug Industry
4	9.4.2026	NICDC – Rejuvenation of export Oriented Industrial clusters

We are glad to share that in response to our representation on Allotment of Ammonia to Bulk Drug Industry, Department of Pharmaceuticals, Government of India proactively taken action by asking GAIL to allot Gas to the manufacturers of Ammonia on top priority.

Advancing pressure protection in biopharma: how integrated bypass technology elevates single-use pump design

In pharmaceutical and biopharmaceutical manufacturing, there is zero margin for error when it comes to process integrity and operator safety. Among the many variables that must be tightly controlled, pressure ranks high on the list.

In pharmaceutical and biopharmaceutical manufacturing, there is zero margin for error when it comes to process integrity and operator safety. Among the many variables that must be tightly controlled, pressure ranks high on the list.

Overpressure or vacuum conditions can compromise not only equipment, but also batch sterility, production timelines, and ultimately, patient safety. Robust pressure protection strategies aren't just best practice – they're mandated by regulatory bodies like the FDA and EMA, and central to Good Manufacturing Practice (GMP).

The case for pressure and vacuum protection

Core systems in biopharma – from bioreactors and buffer tanks to single-use transfer lines – operate within precise pressure thresholds. A sudden spike can rupture vessels or disrupt sterile boundaries, while vacuum conditions can cause structural collapse or introduce air into closed systems. Without adequate safeguards, the consequences are severe: lost batches, regulatory fallout, and operator risk.

Standard pressure protection methods

While no single solution fits every application, the most common pressure protection methods can be grouped into three categories. Each offers distinct benefits and trade-offs depending on system requirements:

- **Rupture Disks:** Rupture disks (or bursting disks) are single-use safety devices engineered to rupture at a predetermined pressure. With no moving parts, they respond rapidly and require minimal maintenance, making them especially suited for aseptic environments. They are compact, cost-effective, and often used where space and sterility are priorities. However, once triggered, rupture disks must be replaced. They can be compromised by improper installation or corrosion, and any released fluids or gases must be safely vented or contained
- **Relief Valves:** Relief valves provide a reusable, adjustable method of pressure control. They open at a preset point to release excess pressure and close once conditions return to normal. These valves are widely used in systems that experience pressure fluctuations, offering a high degree of flexibility and reusability. However, they respond more slowly than rupture disks, require regular maintenance and calibration, and can be prone to leakage or performance drift over time
- **Integrated Bypass Technologies:** An increasingly relevant category

for single-use applications, integrated bypass technologies build pressure protection directly into the equipment itself. These designs simplify system architecture by eliminating the need for external relief valves or rupture disks, instead allowing fluid to be redirected internally when safe pressure limits are exceeded. By reducing system complexity, these technologies support faster changeovers, improved sterility, and greater operational efficiency

As pressure control requirements evolve alongside the adoption of single-use systems, a new generation of integrated solutions is gaining traction – offering embedded safety without sacrificing speed, sterility, or scalability.

Translating pressure protection into practice

One example of this shift is Xylem's Jabsco PureFlo 21 Single Use pump. Designed with both performance and simplicity in mind, the pump incorporates an integrated, adjustable bypass that automatically recirculates fluid within the pump head when pressure thresholds are exceeded.

This allows the system to recover without disruption, eliminating the need for external relief devices and enabling seamless operation under fluctuating conditions.

The pump's self-resetting bypass mechanism helps minimize system downtime by automatically managing excess pressure without manual intervention. Internal recirculation within the pump head maintains sterility and

ensures that product integrity is never compromised, even under fluctuating conditions.

Engineering for efficiency and compliance

By eliminating the need for external tubing and hardware, the PureFlo 21 Single Use simplifies system design and validation, reducing setup complexity and risk of contamination. The PureFlo 21 Single Use offers standard pressure relief settings which are factory-calibrated as well as offering custom settings according to customer specifications.

The PureFlo 21 Single Use incorporates a five-chamber design that ensures ultra-low pulsation, enabling gentle fluid handling even in the most sensitive biologics processes. Its disposable pump head, made of polypropylene, uses less material than comparable designs – offering meaningful environmental benefits without compromising performance.

To support operational agility, the pump features six connection options and a tool-free, click-on interface for fast and secure installation. Each unit is assembled in an ISO 7 cleanroom and produced under an ISO 9001-certified quality system, ensuring reliability and traceability. The integrated pressure relief valve is fully compliant with PED and UKCA standards, reinforcing the pump's readiness for regulatory environments.

A new standard for single-use systems

As biologics manufacturing moves toward faster, more modular production, integrated safety features like those in the PureFlo 21 Single Use offer a compelling edge. By eliminating bulky external hardware, the pump supports smaller system footprints, faster changeovers, and greater confidence in pressure control.

Pressure protection is more than just a regulatory checkbox, it's an opportunity to engineer smarter, cleaner, and more sustainable systems. The PureFlo 21 Single Use delivers on that promise by combining embedded safety, system simplicity, and environmental stewardship in one innovative design.

**Courtesy: Pharmaceutical Technology /Xlem
14.4.2026**

EXPORTS OF BULK DRUGS AND INTERMEDIATES - FEBRUARY 2025 AND 2026				
HS code	Description	Value in US \$ Mn		
		2024-25 (Up to February)	2025-26 (up to February)	% change
17023010	Glucose liquid	52.59	58.79	11.77
17023020	Glucose solid	10.91	7.24	-33.69
17023031	Dextrose,solid	17.78	14.66	-17.53
17023039	Dextrose other than solid	0.27	0.36	37.38
17024039	Dextrose other than solid	0.12	0.05	-53.68
29051410	Ethambutol, ethambutol hcl	8.64	5.55	-35.85
29051420	Salbutamol sulphate	12.90	12.03	-6.81
29054300	Mannitol	8.54	7.26	-14.96
29054400	D-glucitol (sorbitol)	66.73	66.20	-0.79
29071930	Thymol	9.31	7.08	-23.95
29072200	Hydroquinone	10.94	12.81	17.10
29095010	Guaiacol	2.34	2.27	-2.73
29124920	Heliotropin (piperonyl aldehyde)	0.00	0.00	103.89
29124940	3,4,5-trimethoxy-benzaldehyde	2.94	2.00	-31.91
29154010	Monochloroacetic acide their salts and esters	15.21	12.10	-20.45
29163120	Benzyl Benzoate	5.06	3.87	-23.43
29163150	Benzocaine (ethylpara-amino benzoate)	1.68	2.73	62.63
29163400	Phenyl acetic acid	1.10	1.10	-0.06
29171940	Ferrous fumerate	8.65	7.22	-16.49
29171970	Ethoxy methylene malonate, diethyl malonate	0.01	0.26	5168.22
29181120	Calcium lactate	0.19	0.14	-28.64
29181320	Metroprolol tartrate	9.64	9.46	-1.83
29181510	Potassium citrate	3.59	2.02	-43.76
29181520	Sodium citrate	12.77	8.42	-34.11
29181550	Ferric ammonium citrate	0.72	1.07	48.55
29181610	Calcium gluconate	6.79	5.13	-24.38
29181620	Ferrous gluconate	1.18	0.65	-44.55
29182110	Salicylic acid	2.71	3.84	41.68
29182120	Sodium salicylate	2.46	2.23	-9.27
29182200	O-acetylsalicylic acid its salts and estrs	1.60	1.64	2.37
29182310	Methyl salicylate	8.85	8.28	-6.46
29182320	Amino salicylate	0.62	0.53	-14.46
29183030	Nalidixic acid	1.77	0.91	-48.45
29199010	Glycerophosphoric acid	0.03	0.08	148.67
29199030	Iron glycerophosphate	0.04	0.01	-67.30
29214236	Methyl dopa(l-alpha methyl-3, 4-dihydroxyphenylalanine)	0.21	0.42	100.91
29214600	amfetamine INN and its related apis	36.72	56.77	54.60
29215110	o phenylanediaimine	0.64	1.05	62.67
29215120	M-phenylenediaimine (m-di aminobenzene)	11.29	24.06	113.13
29215130	P-phenylenediaimine	11.48	6.88	-40.06
29215170	Para amini acetanalide	0.36	0.53	46.91
29223100	Amfepra none(inn), methdone & mormethadonesalts	0.51	0.79	54.16
29224100	Lysine and its esters salts thereof	1.77	3.72	109.63
29224210	Glutamic acid	0.17	0.25	46.73

29224220	Monosodium glutamate (aginamoto)	0.70	0.60	-14.69
29224400	Tilidine (INN) and its salts	0.57	0.11	-80.44
29224910	Amino acetic acid (glycine)	27.66	18.44	-33.35
29224920	N-methyl taurine	0.08	0.06	-32.61
29225011	Para-amino-salicylic acid	0.00	0.01	702.09
29225013	Procaine hydrochloride	0.10	0.17	69.58
29225015	L-tyrosine(p-hydroxyphenylamine)	0.01	0.01	-55.42
29225021	Frusemide	18.98	18.27	-3.75
29225024	D0mperid0ne	7.69	6.94	-9.78
29231000	Choline and its salts	11.73	9.10	-22.41
29241100	Meprobamate (inn)	7.36	5.46	-25.85
29242910	Acetanilide	0.30	0.19	-37.97
29242960	Pyrazinamide(pyrazine carboxamide)	5.46	3.90	-28.64
29242970	Pretilachlor	0.15	17.31	11574.28
29242980	Paracetamol	70.20	82.62	17.70
29262000	1-Cyanoguanidine (dicyandiamide)	0.00	0.25	13745.31
29263000	Fenproporex (inn) & its salts	0.04	0.00	-99.41
29280010	Isoniazid	1.15	1.32	15.17
29309040	L-cystine (alpha-amino beta-thiopropionic acid)	4.83	0.00	-100.00
29322010	Coumarin,mthylcoumrn & ehylcoumrn-lactones	9.95	10.28	3.29
29329300	3 -Carboxy(Para sulpho- phenyl)-5-Pyrazololne	0.19	0.58	203.52
29329600	Carbofuran	0.30	0.34	15.18
29331100	Phenazone (antipyrin) and its derivatives	9.65	9.57	-0.91
29331910	3-carboxy (para sulpho-phenyl)-5-pyrazolone	1.86	2.46	32.23
29331920	1 (2,5- dichloro-4-sulpho phenyl)-3-methyl 5 Pyrazolone	1.04	7.21	590.50
29331930	3-methyl-1(4-sulpho-O-toluyl-5-pyrazolone)	0.81	0.13	-84.40
29331940	Phenylmethylpyrazolone	0.02	0.03	3.58
29331950	1-phenyl-5-pyrazolone-3-carboxylic acid	0.02	0.02	1.13
29331960	1-(m-sulphophenyl)-3-pyrazolone	0.04	0.08	69.68
29331970	Analgin	0.08	0.00	-100.00
29332910	Tinidazole	3.63	3.92	7.94
29332920	Metronidazole metronidazole benzoate	16.96	17.89	5.47
29332930	Mebendazole	5.46	6.95	27.22
29332940	Dimetridazole	6.81	6.43	-5.48
29332950	Albendazole	14.84	17.62	18.71
29333914	Chlorpheniramine maleate	6.18	5.39	-12.71
29334100	Levorphanol (inn) and its salts	1.57	0.00	-100.00
29335200	Malonylurea (barbituric acid) & its sals	0.70	1.29	83.82
29335300	Allobarbital and othr barbital compnds andits salts	4.05	2.84	-29.79
29335400	Other derivatives of malonylurea (barbituric acid), salts thereof	1.44	1.72	19.98
29335910	Aminophylline(cordophylin)	0.71	0.53	-26.19
29335920	Trimethoprim	13.70	13.93	1.68
29335930	Diethyl carbanazine citrate	1.21	0.35	-70.93
29335940	1-Amino-4-Methyl piperazine	6.16	14.31	132.17
29335950	Bispiribac Sodium(Herbicide)	1.04	8.64	733.04
29339100	Alpra zolam, camazepam & other cmpnds of zepam, salts thereof	19.21	21.00	9.29

29339200	Azinphos-methyl (ISO)	0.11	0.25	138.24
29349100	Aminorex, brotizolam and other like cmpnds, salts thereof	6.07	11.12	83.18
29349200	Fentanyl	0.26	0.54	112.14
29349910	Chloro Thiophene-2-Carboxylic Acid	0.06	0.17	190.43
29349920	Morpholine	15.47	16.68	7.82
29349930	Pramoxine	0.07	6.48	9817.31
29349990	Other Hetrocyclic compounds	645.83	715.57	10.80
29351000	N-Methylperfluorooctane sulphonamide	0.05	0.28	485.74
29352000	N-Ethylperfluorooctane sulphonamide	0.01	0.04	185.89
29355010	Flubendiamide(insecticide)	0.00	0.00	-100.00
29355090	Other Perfluro Octane Suphonomides	2.57	2.84	10.80
29359011	Sulphamethoxazole	33.34	30.42	-8.74
29359012	Sulphafurazole	0.01	0.01	-12.01
29359013	Sulphadiazine	5.72	6.39	11.73
29359014	Sulphadimidine	0.06	0.04	-37.26
29359015	Sulphacetamide	0.01	0.02	105.87
29359022	Sulphamethiazole	3.05	4.55	48.92
29359024	Sulfamide	0.00	0.00	-92.21
29362100	Vitamins a and their derivatives	21.01	21.95	4.45
29362210	Vitamin b1i(thiamine, aneurine) & its salt	11.22	12.57	11.99
29362290	Other vitamin b1i and its drivatives	17.06	12.12	-28.96
29362310	Vitamin b2 (riboflavin, lactoplavin) and its salts	10.14	12.71	25.35
29362390	Other vitamin b2 and its derivatives	0.14	0.17	20.69
29362400	D-or dl-pantothenic acid (vitamin b3 or vitamin b5) and its derivatives	0.90	0.32	-64.84
29362500	Vitamin b6 & its drvts	0.29	0.73	152.72
29362610	Vitamin b12 (cynocobalamin)	0.91	1.30	42.71
29362690	Other vitamin b12 and its derivatives	3.76	8.17	117.01
29362700	Vitamin c (ascorbic acid) & its drvtvs	11.61	12.09	4.13
29362800	Vitamin e and its derivatives	20.51	25.52	24.45
29362910	Folic acid (vitamin b9)	5.17	6.46	24.98
29362920	Nctnc acid & nctnmd(niacinamide/niacine)	91.22	80.70	-11.53
29362930	Vitamin k (menaphthonum b.p.)	9.20	9.11	-0.90
29362940	Vitamin d	23.32	27.75	18.96
29362950	Vitamin h (biOlin)	0.74	0.44	-40.70
29362990	Other vitamins and thr drvtvs	20.96	18.10	-13.64
29369000	Other, incl. natural concentrts	46.73	52.49	12.31
29371100	Somatotropin, its drvtvs& strctl analogves	0.25	0.21	-17.91
29371200	Insulin and its salts	40.53	44.75	10.41
29371900	Other polypeptide hormones thr dtvtvs & strctl anlges	35.10	45.44	29.47
29372100	Cortisone,hydrocortisone,prednisone (dehydrocortisone)and frednisolone and prdnsln(dehydrohydrocortisone)	12.54	12.89	2.77
29372200	Halgntd drvtvs of corti costeroidal	37.98	34.57	-8.98
29372300	Oestrogens and progestogens	27.65	31.24	12.97
29372900	Othr steroidal hormons thr drvtvs and strctl anlges	117.05	123.15	5.21
29373100	Epinethrine	0.01	0.00	-56.05
29375000	Prostaglandins, tiromboxames& leukotrienesthr drvtvs & strctl anlges	2.76	1.39	-49.72

29379011	Epinephrine	0.01	0.00	-100.00
29379019	Other Catecholamine hormones, their derivatives and structural analogues	1.40	0.46	-67.04
29379020	Amino acid Derivatives	23.75	11.37	-52.13
29379090	Other Amino acid Derivatives	24.27	23.51	-3.13
29381000	Rutoside (rutin) and its derivatives	0.02	0.00	-88.82
29389010	Digoxin	1.85	1.61	-12.83
29389090	Other glycosides ntrl/rprcd by synthesis & thr slts ethrs drtvts	49.77	75.82	52.32
29391100	Concentrates of poppy straw cmpnds of morphin, codeine, codone, the baine, salts thereof	2.02	0.27	-86.84
29392010	Quinine alkaloids	0.00	0.00	287.50
29392020	Quinine hydrochloride	2.64	3.90	47.71
29392030	Quinine sulphate	1.09	0.71	-34.61
29392040	Chloroquine phosphate	1.64	1.94	18.01
29393000	Caffeine and its salts	59.59	74.46	24.95
29394100	Ephedrine & its salts	2.16	1.91	-11.30
29394300	Cathine(INN) & its salts	0.25	0.00	-100.00
29394400	Norephedrine and its salts	2.76	3.17	14.84
29394500	Levo Methamphetamine	0.21	0.15	-29.54
29394900	Other ephedrine and its salts	2.81	1.68	-40.32
29395900	Other theophylline and aminophylline thr drtvts, salts	36.69	45.81	24.87
29396110	Ergometrine	0.00	0.00	-100.00
29396190	Other ergometrine salts	0.00	0.00	-100.00
29396210	Ergotamine tartarate	0.00	0.01	44.03
29396900	Other alkaloids of rye ergot & drtvts	2.88	1.72	-40.42
29397900	Other of Vegetable origin	119.01	163.20	37.13
29398000	Non Vegetable Alkaloids	16.63	15.02	-9.68
29411010	Penicillins and its salts	0.02	0.14	467.05
29411020	Ampicilline & its salts	27.32	22.13	-19.00
29411030	Amoxycilline & its salts	184.02	143.35	-22.10
29411040	Cloxacilline & its salts	22.96	20.54	-10.56
29411050	6 - apa	0.00	0.03	0.03
29411090	Other penicillins & thr drtvts with a penicillanic acid strctr slts thereof	83.37	65.17	-21.83
29412010	Streptomycins	0.01	0.04	287.71
29412090	Other streptomycine & drtvts, salts	0.03	0.29	891.73
29413010	Doxycycline & its salts	0.56	1.25	124.18
29413020	Tetracycline/oxytetracycline & hr salts	2.05	0.97	-52.41
29413090	Other tetracyclines & thr drtvts slts	0.54	0.29	-45.95
29414000	Chloramphenicol & its drtvts slts thereof	2.82	2.01	-28.94
29415000	Erythromycin & its drtvts slts thereof	107.77	94.68	-12.15
29419011	Rifampicin	9.83	13.66	38.99
29419013	Rifampicin or Rifampicin Sodium (Rifampin)	0.20	0.00	-100.00
29419014	1-Amino-4-Methyl piperazine (Rifampin)	0.00	0.00	-82.50
29419019	Other rifampicin and its salts	10.72	5.37	-49.88
29419020	Cephalexin & its salts	9.71	7.35	-24.28
29419030	Ciprofloxacin & its salts	24.81	20.68	-16.67
29419040	Gentamycin & its salts	0.05	0.02	-46.22
29419050	Neomycin	0.05	0.09	89.09
29419060	Norfloxacin & its salts	2.37	2.99	26.05
29419090	Other antibiotics	564.24	511.80	-9.29

29420011	Cefadroxil	19.52	13.99	-28.34
29420012	Ibuprofane	72.91	70.40	-3.44
29420013	Nifedipine	1.85	3.08	66.75
29420014	Ranitidine	9.75	8.00	-18.02
29420015	Danes salt of D(-) phenyl glycine	0.15	0.00	-100.00
29420016	Timolo maleate, terbutoline sulphate, imipramine HCl, amitryptiline, Atenolol,Propanolol	0.15	0.02	-85.03
29420021	Timolol maleate	4.91	4.64	-5.42
29420022	Terbutoline sulphate	1.23	1.35	9.96
29420024	Imipramine hcl	0.61	0.72	18.36
29420025	Amitryptiline hcl	5.79	6.44	11.17
29420026	Cysteanune hcl	0.00	0.00	-94.64
29420027	Atenolol, propronalol	10.88	10.96	0.72
29420031	Diloxanide furoate	3.47	3.70	6.77
29420032	Cimetidine	0.02	0.08	289.62
29420033	Oxyclozanide	6.41	9.40	46.52
29420034	Famotidine	14.22	13.84	-2.63
29420090	Other diloxanide furoate, cimetidine, famotidine nes	1122.71	1098.22	-2.18
96020030	Gelatin capsules,empty	86.55	75.26	-13.05
	Grand Total	4683.99	4732.13	

India's Imports of Bulk Drugs by HS code \$ Mn				
HS code	Description	2024-25 (up to Feb)	2025-26 (up to Feb)	Change
17023010	Glucose liquid	0.09	0.10	16.96
17023020	Glucose solid	0.75	0.52	-30.95
17023031	Dextrose,solid	0.75	0.47	-36.51
17023039	Dextrose other than solid	0.99	1.55	57.46
17024039	Dextrose other than solid	0.32	0.13	-57.74
29051410	Ethambutol, ethambutol hcl	4.50	2.83	-37.06
29051420	Salbutamol sulphate	0.26	0.43	66.91
29054300	Mannitol	51.91	51.90	-0.01
29054400	D-glucitol (sorbitol)	10.78	10.41	-3.46
29071930	Thymol	0.09	0.11	21.55
29072200	Hydroquinone	38.81	34.48	-11.16
29095010	Guaiacol	1.96	3.40	74.01
29124930	Thiacetazone	0.01	0.00	-100.00
29124940	3,4,5-trimethoxy-benzaldeh	0.40	0.37	-6.42
29154010	Monochloroacetic acide the	2.28	1.20	-47.58
29163120	Benzyl Benzoate	0.60	0.79	31.94
29163150	Benzocaine (ethylpara-amin	0.04	0.10	168.67
29163400	Phenyl acetic acid	5.80	1.50	-74.05
29171940	Ferrous fumerate	0.05	0.06	38.80
29171970	Ethoxy methylene malonate	19.70	14.29	-27.46
29181120	Calcium lactate	0.37	0.27	-26.55
29181320	Metroprolol tartrate	1.36	1.35	-0.96
29181510	Potassium citrate	1.86	0.69	-62.87
29181520	Sodium citrate	2.33	4.40	89.19
29181550	Ferric ammonium citrate	0.02	0.03	36.35
29181610	Calcium gluconate	9.06	6.82	-24.74
29182110	Salicylic acid	25.53	19.41	-23.96
29182120	Sodium salicylate	0.06	0.12	107.06
29182200	O-acetylsalicylic acid its salts	0.66	0.73	9.32
29182310	Methyl salicylate	1.49	0.90	-39.76
29183030	Nalidixic acid	0.72	0.60	-16.60
29199010	Glycerophosphoric acid	0.00	0.04	1689.24
29214600	amfetamine INN and its rela	0.44	0.33	-23.24
29215110	o phenylanediaamine	15.77	10.16	-35.60
29215120	M-phenylenediaamine (m-di	4.07	4.27	4.91
29215130	P-phenylenediaamine	5.14	4.10	-20.26
29223100	Amfepra none(inn), methdo	0.00	0.00	2280.30
29224100	Lysine and its esters salts th	135.56	106.13	-21.71
29224210	Glutamic acid	0.70	1.01	44.55
29224220	Monosodium glutamate (ag	57.98	67.90	17.12
29224910	Amino acetic acid (glycine)	25.68	19.03	-25.90
29224920	N-methyl taurine	1.21	3.98	228.12
29225011	Para-amino-salicylic acid	0.35	0.02	-93.78
29225013	Procaine hydrochloride	0.02	0.02	-0.13
29225015	L-tyrosine(p-hydroxyphenyl	2.90	3.47	19.90
29225021	Frusemide	0.42	0.48	13.15
29231000	Choline and its salts	2.93	1.93	-34.09

29241100	Meprobamate (inn)	2.03	1.32	-35.06
29242910	Acetanilide	13.45	12.89	-4.16
29242960	Pyrazinamide(pyrazine carb	1.46	0.67	-53.73
29242970	Pretilachlor	2.43	3.49	43.35
29242980	Paracetamol	6.90	10.87	57.65
29262000	1-Cyanoguanidine (dicyandi	71.93	56.96	-20.82
29263000	Fenproporex (inn) & its salts	0.00	0.95	3.30
29264000	Alpha-phenylacetoacetoneitr	0.11	0.20	88.49
29280010	Isoniazid	1.72	2.74	59.01
29309040	L-cystine (alpha-amino beta	18.67	0.00	-100.00
29322010	Coumarin,mthylcoumrn & e	0.88	0.61	-30.83
29329300	3 -Carboxy(Para sulpho- phe	2.73	1.52	-44.34
29331100	Phenazone (antipyrin) and it	1.23	1.66	34.48
29331910	3-carboxy (para sulpho-phe	0.14	0.60	322.15
29331920	1 (2,5- dichloro-4-sulpho ph	0.17	0.41	150.55
29331930	3-methyl-1(4-sulpho-O-tolu	0.00	0.00	-23.94
29331940	Phenylmethylpyrazolone	0.82	0.66	-19.71
29331950	1-phenyl-5-pyrazolone-3-ca	0.00	1.09	3.09
29331960	1-(m-sulphophenyl)-3-pyraz	0.28	0.49	78.45
29331970	Analgin	4.50	2.95	-34.51
29331980	Oxyphenbutazone	0.01	0.15	1005.35
29332910	Tinidazole	0.34	0.33	-4.70
29332920	Metronidazole metronidazo	10.94	7.95	-27.33
29332930	Mebendazole	0.12	0.17	46.65
29332940	Dimetridazole	0.12	0.00	-96.53
29335200	Malonylurea (barbituric acid	4.58	5.33	16.28
29335300	Allobarbital and othr barbita	0.19	0.05	-71.56
29335400	Other derivatives of malony	0.32	1.04	229.06
29335500	Loprazolam, mecloqualone,	0.00	0.00	222.63
29335910	Aminophylline(cordophylin)	0.80	0.16	-80.02
29335920	Trimethoprim	0.25	0.33	33.32
29335940	1-Amino-4-Methyl piperazin	0.01	0.02	53.96
29335950	Bispiribac Sodium(Herbicid	0.01	0.45	7050.08
29339100	Alpra zolam, camazepam &	2.26	1.49	-34.09
29339200	Azinphos-methyl (ISO)	0.00	0.00	267.00
29349100	Aminorex, brotizolam and o	0.03	0.00	-98.46
29349200	Fentanyl	0.54	0.39	-26.85
29349910	Chloro Thiophene-2-Carbox	0.84	0.79	-6.46
29349930	Pramoxine	0.00	0.02	510.62
29349990	Other Hetrocyclic compoun	654.10	685.75	4.84
29351000	N-Methylperfluorooctane s	0.02	0.02	9.30
29355090	Other Perfluro Octane Suph	0.10	0.97	836.49
29359011	Sulphamethoxazole	0.03	0.04	46.47
29359013	Sulphadiazine	0.69	0.76	10.05
29359014	Sulphadimidine	1.44	1.97	37.08
29359022	Sulphamethiazole	0.00	0.00	-100.00
29359023	Sulphamoxole	0.00	0.00	-100.00
29359024	Sulfamide	0.83	1.20	45.77
29362100	Vitamins a and their derivat	15.12	21.62	43.01
29362210	Vitamin b1i(thiamine, aneur	19.06	25.15	31.95

29362290	Other vitamin b1i and its dri	3.50	2.60	-25.73
29362310	Vitamin b2 (riboflavin, lacto	11.78	9.27	-21.29
29362390	Other vitamin b2 and its der	4.48	2.95	-34.07
29362400	D-or dl-pantothenic acid (vit	9.68	11.01	13.68
29362500	Vitamin b6 & its drvts	14.56	13.99	-3.89
29362610	Vitamin b12 (cynocobalamin	26.63	33.42	25.51
29362690	Other vitamin b12 and its de	1.47	3.50	138.49
29362700	Vitamin c (ascorbic acid) & i	25.47	34.84	36.80
29362800	Vitamin e and its derivatives	42.49	55.25	30.03
29362910	Folic acid (vitamin b9)	3.59	6.52	81.51
29362920	Nctnc acid & nctnmd(niacin	1.87	1.22	-34.79
29362930	Vitamin k (menaphthonum	2.42	2.06	-14.89
29362940	Vitamin d	14.67	14.40	-1.85
29362950	Vitamin h (biOlin)	1.56	1.72	10.06
29362990	Other vitamins and thr drvtv	18.93	13.07	-30.98
29369000	Other, incl. natural concentr	1.25	2.91	133.27
29371100	Somatotropin, its drvts& st	0.01	0.00	-53.09
29371200	Insulin and its salts	33.68	48.45	43.85
29371900	Other polypeptide hormone	46.84	68.85	46.98
29372100	Cortisone,hydrocortisone,pr	39.48	35.88	-9.12
29372200	Halgntd drvtvs of corti coste	27.92	29.33	5.08
29372300	Oestrogens and progestoge	64.30	53.69	-16.51
29372900	Othr steroidal hormons thr	108.45	103.98	-4.12
29375000	Prostaglandins, tiromboxam	9.17	8.31	-9.40
29379011	Epinethrine	0.00	0.28	16334.80
29379019	Other Catecholamine horm	6.00	4.23	-29.52
29379020	Amino acide Derivatives	11.03	8.81	-20.13
29379090	Other Amino acide Derivatv	56.85	57.15	0.53
29381000	Rutoside (rutin) and its deriv	4.58	4.49	-2.00
29389010	Digoxin	0.03	0.16	500.53
29389020	Digitalis glycosides	0.09	0.06	-33.25
29389090	Other glycosides ntrl/rprdc	77.40	64.53	-16.63
29391100	Concentrates of poppy stra	27.03	7.13	-73.64
29392010	Quinine alkaloids	0.67	1.30	94.68
29392020	Quinine hydrochloride	0.00	0.30	7618.35
29392030	Quinine sulphate	0.51	0.84	63.87
29393000	Caffeine and its salts	23.62	37.71	59.62
29394100	Ephedrine & its salts	0.01	0.10	598.49
29394300	Cathine(INN) & its salts	0.00	0.00	375.80
29394400	Norephedrine and its salts	0.00	0.01	1766.46
29394500	Levo Methaphatamine	0.00	0.00	-37.57
29394900	Other ephedrives and thr sa	0.57	0.73	28.94
29395900	Other theophylline and ami	4.17	6.14	47.16
29396190	Other ergometrine salts	0.12	0.41	241.82
29396210	Ergotamine tartarate	0.74	0.52	-29.22
29396290	Other ergotamine salts	0.10	0.00	-100.00
29396300	Lysergic acid and its salts	0.01	0.00	-100.00
29396900	Other alkaloids of rye ergot	3.18	3.61	13.35
29397200	Cocaine, ecgonine, levomet	0.26	0.00	-99.57
29397900	Other of Vegitable origin	5.78	10.08	74.48

29398000	Non Vegetable Alkaloids	8.63	5.37	-37.81
29411010	Penicillins and its salts	232.05	109.18	-52.95
29411020	Ampicilline & its salts	0.39	0.56	42.79
29411030	Amoxycilline & its salts	42.99	34.95	-18.72
29411040	Cloxacilline & its salts	0.57	0.97	70.84
29411050	6 - apa	424.98	342.82	-19.33
29411090	Other penicillins & thr drvtv	82.81	91.30	10.25
29412010	Streptomycins	4.65	4.75	2.07
29412090	Other streptomycine & drvt	2.31	2.30	-0.48
29413010	Doxycylime & its salts	22.21	26.75	20.43
29413020	Tetracycline/oxytetra - cycli	11.44	12.38	8.22
29413090	Other tetracyclines & thr dr	24.64	26.64	8.13
29414000	Chloramphenicol & its drvtv	2.50	0.82	-67.15
29415000	Erthromycin & its drvtvs slts	170.29	189.82	11.47
29419011	Rifampicin	44.50	45.93	3.21
29419013	Rifa S or Rifa S Sodium (Rifai	15.44	35.18	127.86
29419014	1-Amino-4-Methyl piperazin	0.08	0.00	-100.00
29419019	Other rifampicin and its salt	55.84	58.15	4.13
29419020	Cephalexin & its salts	34.73	26.69	-23.14
29419030	Ciprofloxacin & its salts	9.52	5.36	-43.72
29419040	Gentamycin & its salts	8.54	9.65	13.08
29419050	Neomycin	2.55	3.16	24.10
29419060	Norfloxacin & its salts	12.32	8.15	-33.88
29419090	Other antibiotics	788.08	830.82	5.42
29420011	Cefadroxil	1.70	2.25	31.73
29420012	Ibuprofane	7.97	7.85	-1.54
29420013	Nifedipine	0.01	0.40	3919.37
29420014	Ranitidine	0.11	0.19	65.93
29420015	Danes salt of D(-) phenyl gly	19.03	19.64	3.20
29420016	Timolo maleate, terbutoline	27.32	25.44	-6.90
29420021	Timolol maleate	0.31	0.37	20.26
29420025	Amitriptyline hcl	0.03	0.00	-100.00
29420026	Cysteanune hcl	2.85	4.48	57.07
29420027	Atenolol, propronalol	1.19	1.64	37.33
29420032	Cimetidine	0.65	1.44	123.08
29420033	Oxyclozanide	0.01	0.00	-100.00
29420034	Famotidine	0.21	0.38	79.00
29420090	Other diloxanide furoate, ci	332.30	306.25	-7.84
96020030	Gelatin capsules,empty	6.07	4.68	-22.90
Grand Total		4417.73	4267.19	-3.41



GLOBAL ChemShow™
International Exhibition 2026

Hall no: 4

Bombay Exhibition Centre,
Mumbai, India

14-15 December 2026

**Booth Bookings
now open -
Secure your Premium
Space today**



300+ Exhibitors | 22,000+ Trade Visitors | International Attendees

**Bulk, Fine & Speciality Chemicals, API's, Pharma Intermediates,
Pharma Raw Materials, Pharma Excipients, Pharma Formulations,
Custom Synthesis & Research, Contract Manufacturing,
Process Technology Expo**

Media Partner



Organised by



Supporting
Association



Contact : Ms. Roja Rani : +91-92461 83424 | www.globalchemshow.com

Special offer to BDMAI Members:

The organizers of Global Chem Show offer 30 fully built up 9 sq. meter stalls to BDMAI members **Free of Cost**. The objective of this offer is to promote participation of APIs & Intermediates, Pellets manufacturers in this show.

BDMAI's participation in this show last year was successful with 17 member companies participating in the Pavilion.

All members are requested to take advantage of this unique opportunity. Interested members may contact us at info@bdmai.org; ed@bdmai.org